Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age

Article Medicine, General & Internal

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age

E. B. Walter et al.

Summary: A regimen of two 10-mu g doses of BNT162b2 administered 21 days apart was found to be safe, immunogenic, and efficacious in children aged 5 to 11 years.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Multidisciplinary Sciences

Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection

Jing Zou et al.

Summary: The spread of the Omicron SARS-CoV-2 variant highlights the importance of analyzing the cross-protection provided by previous non-Omicron infections. A new study shows that patients with prior non-Omicron infections do not develop strong neutralization against Omicron. This supports the vaccination of previously infected individuals to mitigate the impact of the ongoing Omicron surge.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

Mark G. Thompson et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection

Article Infectious Diseases

COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA. 2 subvariants - surveillance results from southern Sweden, December 2021 to March 2022

Jonas Bjork et al.

Summary: We compared the effectiveness of vaccines against severe COVID-19 during the period of December 2021 to March 2022, when Omicron BA.1 and BA.2 variants were dominant in Scania county, Sweden. The effectiveness remained above 80% for individuals with at least three vaccine doses, but decreased to 54% for those with only two doses. Protection from prior infection was also lower after the transition to BA.2. Booster vaccination appears to be necessary to maintain sufficient protection.

EUROSURVEILLANCE (2022)

Add to Collection

Article Medicine, Research & Experimental

Coronavirus disease 2019 transmission and symptoms in young children during the severe acute respiratory syndrome coronavirus 2 Delta variant and Omicron variant outbreaks

Tetsuya Akaishi et al.

Summary: The study found that the secondary transmission rate of the Delta and Omicron variants after close contact with young children was significantly higher than that of conventional strains, and the symptoms in young children infected with the Delta and Omicron variants were similar.

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2022)

Add to Collection

Article Medicine, General & Internal

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine

Edson D. Moreira et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting

Ori Magen et al.

Summary: The use of a fourth dose of BNT162b2 vaccine in Israel starting on January 3, 2022, has shown significant reductions in infection rate, symptomatic infection, hospitalization, and Covid-19-related deaths by February 18.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Hospitalization of Infants and Children Aged 0–4 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February 2022

Kristin J. Marks et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022

Nicola P. Klein et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection

Editorial Material Pediatrics

COVID-19 Vaccines in Infants, Children, and Adolescents

Yvonne A. Maldonado et al.

PEDIATRICS (2022)

Add to Collection

Article Multidisciplinary Sciences

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine

Tal Patalon et al.

Summary: In this retrospective study, the authors demonstrate a significant waning of mRNA vaccine effectiveness against the Omicron variant of SARS-CoV-2 infection within a few months after administration of the third dose of the BioNTech/Pfizer BNT162b2 vaccine.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Multidisciplinary Sciences

Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine

Chaitanya Kurhade et al.

Summary: This study found that sera from individuals vaccinated with three doses of BNT162b2 have lower neutralization efficacy against Omicron BA.1, BA.2, and BA.3 compared to the original strain USAWA1/2020. The results have implications for vaccine strategy and understanding the biology of Omicron sublineages.

NATURE COMMUNICATIONS (2022)

Add to Collection

Letter Pediatrics

Childcare and Employment Disruptions in 2020 Among Caregivers of Children With and Without Special Health Care Needs

Caleb Easterly et al.

JAMA PEDIATRICS (2022)

Add to Collection

Review Pediatrics

Risk Factors for Severity in Children with Coronavirus Disease 2019 A Comprehensive Literature Review

Sophia Tsabouri et al.

PEDIATRIC CLINICS OF NORTH AMERICA (2021)

Add to Collection

Article Medicine, General & Internal

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study

Noam Barda et al.

Summary: A study using data from Israel's largest health-care organization showed that a third dose of the BNT162b2 mRNA vaccine is effective in preventing individuals from severe COVID-19-related outcomes, compared to receiving only two doses at least 5 months ago. The effectiveness of the third dose in preventing hospital admission was 93%, severe disease 92%, and COVID-19-related death 81%.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

Robert W. Frenck et al.

Summary: The BNT162b2 vaccine showed favorable safety profile and a greater immune response in 12-to-15-year-old recipients compared to young adults, and demonstrated high effectiveness against Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3

Ann R. Falsey et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Pediatrics

Association of Age and Pediatric Household Transmission of SARS-CoV-2 Infection

Lauren A. Paul et al.

Summary: This study suggests that younger children, especially those aged 0 to 3 years, may have a higher risk of transmitting SARS-CoV-2 compared to older children. The differential infectivity of pediatric age groups has implications for infection prevention strategies within households and educational settings. Further population-based studies are needed to fully understand the transmission risk posed by younger pediatric index cases.

JAMA PEDIATRICS (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19-COVID-NET, 14 States, March 1-July 25, 2020

Lindsay Kim et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2020)

Add to Collection

Article Medicine, General & Internal

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age

Related references

Export Citation

Share Paper